CQA 206–291
| Autor: | M Hoyer, Olivier Rascol, X Lataste, C Lücking, D Hirt, Werner Poewe, Urpo K. Rinne, H Teräväinen, E Dupont, N Fabre |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Pharmacology
medicine.medical_specialty Levodopa Parkinson's disease business.industry medicine.disease Dopamine agonist Effective dose (pharmacology) Endocrinology Tolerability Dopamine Antiparkinson Agents Internal medicine Medicine Pharmacology (medical) Neurology (clinical) business Adverse effect medicine.drug |
| Zdroj: | Clinical Neuropharmacology. 13:303-311 |
| ISSN: | 0362-5664 |
| DOI: | 10.1097/00002826-199008000-00004 |
| Popis: | The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|